2 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Graves Orbitopathy: new trials by email Literature Review of Graves Orbitopathy trials Research Report on Graves Orbitopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease LASN01, Placebo - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 2 | Completed | Lassen Therapeutics Inc. | 41 | 2024-03-05 | 2026-03-09 |
| A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Linsitinib, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Completed | Sling Therapeutics, Inc. | 90 | 2022-07-01 | 2026-09-23 |
Endocrine System Diseases (2) · Exophthalmos (2) · Eye Diseases (2) · Graves Ophthalmopathy (2) · Orbital Diseases (2) · Hashimoto Disease (1) · Thyroid Diseases (1)
Autoimmune Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Goiter (2) · Graves Disease (2) · Hyperthyroidism (2) · Immune System Diseases (2) · Thyroid Diseases (1) · Thyroiditis (1) · Thyroiditis, Autoimmune (1)
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1)
Lassen Therapeutics Inc. (1) · Sling Therapeutics, Inc. (1)
Spain (2) · United Kingdom (2) · United States (2) · Canada (1) · Italy (1)